nitroglycerin has been researched along with glucagon-like peptide 1 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahrén, B; Gutniak, MK; Holst, JJ; Nyström, T; Sjöholm, A; Zhang, F; Zhang, Q | 1 |
| Cao, F; Chen, X; Kim, TH; Ma, N; Niu, G; Sun, Z; Tong, G | 1 |
1 trial(s) available for nitroglycerin and glucagon-like peptide 1
| Article | Year |
|---|---|
Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.
Topics: Adult; Brachial Artery; Coronary Circulation; Coronary Disease; Coronary Vessels; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelial Cells; Endothelium, Vascular; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Insulin; Male; Middle Aged; Nitroglycerin; Peptide Fragments; Pilot Projects; Protein Precursors; Receptors, Glucagon; Regional Blood Flow; Vasodilation | 2004 |
1 other study(ies) available for nitroglycerin and glucagon-like peptide 1
| Article | Year |
|---|---|
PEGylated exendin-4, a modified GLP-1 analog exhibits more potent cardioprotection than its unmodified parent molecule on a dose to dose basis in a murine model of myocardial infarction.
Topics: Aminophylline; Animals; Atropine; Blotting, Western; Cardiovascular Agents; Disease Models, Animal; Drug Combinations; Exenatide; Glucagon-Like Peptide 1; Heart; Heart Function Tests; Histocytochemistry; Male; Mice, Inbred C57BL; Myocardial Infarction; Myocardium; Neovascularization, Physiologic; Nitroglycerin; Papaverine; Peptides; Phenobarbital; Survival Analysis; Treatment Outcome; Venoms | 2015 |